CDT Equity Inc.
CDT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CDT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CDT
CDT Equity Inc. is a pre-revenue biotech company using AI and solid-form technology to repurpose and extend the patent life of de-prioritized pharmaceutical assets, targeting autoimmune, infertility, dermatology, and animal health indications.
Key risk: Cash runway uncertainty
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.3M
Cash Runway
—
Lead Asset
AZD1656 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates for CDT Equity Inc..
CDT Equity Inc. is a pre-revenue biotech company using AI and solid-form technology to repurpose and extend the patent life of de-prioritized pharmaceutical assets, targeting autoimmune, infertility, dermatology, and animal health indications.
- Pipeline targets inflammatory/autoimmune disorders, idiopathic male infertility, dermatology, rare disease, and animal health [sec_mda · as of 2026-08-12].
- AI-powered disease mapping from Sarborg partnership analyzes over 3,000 disease signatures to identify repurposing opportunities [sec_mda · as of 2026-08-12].
- Cash & equivalents of $0.7M as of 2026-06-30, with a net loss of -$4.6M for the period [sec].
- Lead candidate is a cocrystal of AZD1656 (HK-4 Glucokinase Activator) aimed at extending patent life [sec_mda · as of 2026-04-15].
- Business model focuses on pre-clinical development and out-licensing, avoiding late-stage trial costs [sec_mda · as of 2026-08-12].
What works
- Lean, disease-agnostic model prioritizes capital efficiency and avoids late-stage clinical trial costs [sec_mda · as of 2026-08-12].
- Sarborg AI partnership provides access to over 3,000 disease signatures and has generated two new combination patent filings [sec_mda · as of 2026-08-12].
- Management includes experienced executives such as Dr. Andrew Regan (CEO) and James Bligh (CFO) [sec_mda · as of 2026-08-12].
- Retains 100% ownership of all human-related IP and data generated from the Sarborg collaboration [sec_mda · as of 2026-08-12].
What to weigh
- Cash position of $0.7M as of 2026-06-30 is very limited relative to ongoing R&D needs [sec].
- Accumulated deficit of $17.9M as of 2025-11-13, with no revenue from product sales [sec_mda · as of 2025-11-13].
- All pipeline candidates are at pre-clinical stage; no assurance of successful licensing or commercialization [sec_mda · as of 2026-08-12].
- Dependence on external financing (equity/debt/partnerships) to fund operations, with risk of dilution or unfavorable terms [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
AI-driven repurposing platform uses over 3,000 disease signatures
“apply proprietary algorithms utilizing AI-powered disease mapping to identify novel re-purposing opportunities across a database of more than 3,000 disease signatures”
SEC MD&A · August 12, 2026
Business model relies on out-licensing after pre-clinical trials
“The Company will seek an exit through third-party license deals following successful in vitro and in vivo pre-clinical trials”
SEC MD&A · August 12, 2026
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — With only $0.7M cash as of 2026-06-30 and ongoing R&D costs, the company may need near-term financing [sec].
- Pre-clinical stage pipeline — All assets are pre-clinical; no candidates have entered human trials or received FDA approval [sec_mda · as of 2026-08-12].
- Dependence on external financing — Company relies on equity/debt or partnerships to fund operations; may not secure favorable terms [sec_mda · as of 2026-08-12].
- No revenue from product sales — Company has no commercialized products and expects to generate revenue only through licensing deals [sec_mda · as of 2026-08-12].
What to watch
- Progress of pre-clinical in vitro/in vivo studies for pipeline candidates [sec_mda · as of 2026-08-12].
- Ability to secure additional financing or strategic partnerships [sec_mda · as of 2026-08-12].
- Outcome of Sarborg AI-driven repurposing insights and any new patent filings [sec_mda · as of 2026-08-12].
- Potential licensing deals for AZD1656 cocrystal or other assets [sec_mda · as of 2026-08-12].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run CDT Equity Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CDT Equity Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.23 · 0% dilution
Lead: Preclinical
3 candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$10
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 2 | $10 |
Short Interest
as of May 20, 2026- % of float
- 1.1%
- Days to cover
- 0.2
- Shares short
- 29,314
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CDT short interestGovernance
Frequently asked questions
What is the AI investment thesis for CDT Equity Inc.?
CDT Equity Inc. is a pre-revenue biotech company using AI and solid-form technology to repurpose and extend the patent life of de-prioritized pharmaceutical assets, targeting autoimmune, infertility, dermatology, and animal health indications.
What is CDT Equity Inc.'s lead drug candidate?
CDT Equity Inc.'s most advanced tracked candidate is AZD1656 (Preclinical) for Autoimmune disorders.
Who is the CEO of CDT Equity Inc.?
Dr. Andrew Regan is the chief executive officer of CDT Equity Inc. (CDT).
Where is CDT Equity Inc. headquartered?
CDT Equity Inc. (CDT) is headquartered in Naples, FL, United States.
What therapeutic areas does CDT Equity Inc. focus on?
CDT Equity Inc. develops therapies across Immunology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.